NVIDIA And 2 Elite Undervalued Stocks To Own Sasha Jovanovic Wed, October 7, 2026 at 5:24 AM EDT 5 min read AVGO +3.67% NVDA +0.14% VRTX -0.24% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Global public debt now sits near 100% of GDP, and the IMF is signaling a return to spending cuts and tighter money. That kind of backdrop often pushes investors toward companies that generate solid cash, carry sensible debt levels, and still trade as if they are largely overlooked. This article breaks down three such high quality but ignored US stocks from our screener and explains why they may warrant a closer look.
The three stocks covered below are just a starting sample, since the full screen surfaced 24 more companies with equally detailed stories that are not included here.
If you want to identify and analyze the highest conviction ideas first, go straight to the High Quality Undervalued Stocks screener.
NVIDIA is best known for graphics chips, but the real link to the High Quality Undervalued Stocks theme is its large Compute & Networking business, which provides AI infrastructure for data centers and powers much of the company's cash generation potential.
NVIDIA generated about US$275.4b from Compute & Networking and US$27.6b from Graphics, reflecting a heavy skew toward AI infrastructure, and the business carries a market cap of roughly US$5.77t.
NVIDIA's AI stack sits in the middle of how governments, hyperscalers, and enterprises want to build and run large models. This positioning is a key reason this stock features in a value plus breakout screen in the first place.
"Uptake of an open-source/cheaper/better platform than Nvidia's CUDA would heavily undermine Nvidia's moat and enable any sizeable firm to directly engage semiconductor manufacturers, such as TSMC, to produce their own chips, stealing away Nvidia's high margin products."
The question is what happens to NVIDIA's margins and cash engine if a single key assumption about future customer buying power quietly starts to fray.
If that pressure point matters to you, read the full narrative for NVIDIA to see how NVIDIA's moat, pricing power, and AI demand could still be diverging from older assumptions.
Broadcom ties into the High Quality Undervalued Stocks theme through its VMware based infrastructure software, where recurring subscriptions sit alongside a much larger chip operation that feeds AI networking, storage, broadband, and industrial customers worldwide.
Broadcom Inc. blends semiconductor hardware with infrastructure software, with about US$59.4b from Semiconductor Solutions and US$29.7b from Infrastructure Software, which includes VMware subscriptions linked to the screener theme, and carries a market value close to US$1.73t.
For this screen, Broadcom matters because the Infrastructure Software arm, especially VMware based private cloud and security products, gives the chip maker a recurring cash engine that fits neatly with an undervalued, high quality profile.
"Broadcom is generating substantial free cash flow, expanding its custom silicon business, strengthening its position in networking, and integrating software assets that further diversify earnings."
What happens to that story if a single assumption about how long hyperscalers keep spending at this pace quietly starts to shift?
If that spending curve does bend, read the full narrative for Broadcom to see how Broadcom's cash engine, AI exposure, and software mix could still be decoupling from old assumptions.
Vertex Pharmaceuticals leans on a powerful cystic fibrosis franchise to generate cash, which funds a wider pipeline across renal, endocrine, and rare diseases. This fits the High Quality Undervalued Stocks theme by pairing current cash strength with potential future breakout drivers.
Vertex Pharmaceuticals earns about US$12.6b from its pharmaceuticals portfolio, spanning CF therapies and newer rare disease treatments, and holds a market cap near US$127.6b.
Vertex Pharmaceuticals is using its CF cash engine to back late stage programs that could reshape its mix of therapies in serious kidney conditions.
"Expansion of the renal disease portfolio, including late stage programs like povetacicept in IgA nephropathy with what management describes as best in class numerical reductions in proteinuria and favorable auto injector dosing, and inaxaplin in APOL1 mediated kidney disease with significant UACR reductions and an interim 1 year eGFR readout planned in early 2027, is supported by growing regulatory acceptance of proteinuria and 1 year eGFR endpoints."
What happens to Vertex Pharmaceuticals' earnings path if a single assumption about how quickly that broader franchise scales turns out to be wrong?
That assumption could be masking where the next leg of Vertex Pharmaceuticals' story really comes from, so read the full narrative for Vertex Pharmaceuticals to see how the wider pipeline might reshape the upside.
New breakouts and fresh momentum often get caught by early screens long before headlines move. Use that edge while it matters and before ideas drop off the radar, and consider acting while conditions still fit your criteria.
Spot early trend shifts in smaller companies before they are widely talked about by running the 11 elite penny stocks with strong financials and filtering for stronger balance sheets and cash profiles.
Follow business momentum in automation by scanning the curated 87 robotics and automation stocks and focusing on operators building recurring revenue from industrial and enterprise customers.
Track under-the-radar infrastructure tied to electrification by reviewing the hand picked 44 power grid technology and infrastructure stocks and shortlisting businesses with durable cash flow support.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
